Sir,
Intravitreal triamcinolone acetonide (IVTA) injection is a relatively safe and effective treatment for macular edema in patients with branch retinal vein occlusion (BRVO).1, 2 However, IVTA sometimes causes increased intraocular pressure (IIOP) within 3 months of injection. In our clinical experience, IVTA treatment accompanied by IIOP facilitates reduction of macular edema.3, 4 Therefore, we reviewed the medical records of 43 BRVO patients who had received IVTA. Intraocular pressure (IOP) was assessed, best-corrected visual acuity (BCVA) was recorded, and total macular volume (TMV) and central retinal thickness (CRT) were measured using Stratus optical coherence tomography (OCT; Carl Zeiss Meditec Inc., Dublin, CA, USA). Data were collected before injection, and 1 month and 3 months after injection. Pre-injection mean IOP was 13±3 mm Hg and the 1-month mean IOP was 21±7 mm Hg. Using the 1-month IOP figures, we defined a ‘steroid responder’ as an eye that had an IOP >22 mm Hg. All other eyes were considered to be non-responders. We compared changes between steroid responders and non-responders in BCVA, CRT, and TMV (with reference to pre-injection values) at 1 month and 3 months following injection.
After injection, BCVA, CRT, and TMV improved in both responders and non-responders at the 1-month and 3-month follow-ups (Table 1). Although both responders and non-responders thus exhibited treatment effects, responders showed a greater extent of reduction in macular edema than did non-responders at 1-month follow-up (Figure 1). Responders also showed a greater improvement in visual acuity, with clinical significance, than did non-responders (Mann–Whitney U-test; P=0.027). On OCT, steroid responders exhibited a greater extent of TMV change than did non-responders (P=0.025). TMV changes (from pre-injection to 1-month follow-up) were 2.59±2.70 mm3 (responders) and 1.02±1.26 mm3 (non-responders). Responders showed a greater extent of CRT reduction than did non-responders (P=0.046). CRT changes (from pre-injection to 1-month follow-up) were 268±183 μm (responders) and 178±150 μm (non-responders).
In conclusion, following injection of IVTA to treat BRVO, steroid responders experienced a greater reduction in macular edema than did non-responders. We suggest that some unknown feature(s) of responders with high IOP enables steroids to reduce retinal edema.
References
Cekic O, Chang S, Tseng JJ, Barile GR, Del Priore LV, Weissman H et al. Intravitreal triamcinolone injection for treatment of macular edema secondary to branch retinal vein occlusion. Retina 2005; 25: 851–855.
Lee H, Shah GK . Intravitreal triamcinolone as primary treatment of cystoids macular edema secondary to branch retinal vein occlusion. Retina 2005; 25: 551–555.
Rhee DJ, Peck RE, Belmont J, Martidis A, Liu M, Chang J et al. Intraocular pressure alterations following intravitreal triamcinolone acetonide. Br J Ophthalmol 2006; 90: 999–1003.
Jonas JB, Kreissig I, Degenring R . Intraocular pressure after intravitreal injection of triamcinolone acetonide. Br J Ophthalmol 2003; 87: 24–27.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Chae, J., Joe, S., Yang, S. et al. An increase in intraocular pressure after intravitreal steroid injection facilitates reduction of macular edema. Eye 26, 479–480 (2012). https://doi.org/10.1038/eye.2011.310
Published:
Issue Date:
DOI: https://doi.org/10.1038/eye.2011.310
This article is cited by
-
Surgical results of Ahmed valve implantation combined with intravitreal triamcinolone acetonide injection for preventing choroidal detachment
BMC Ophthalmology (2015)
-
Intraocular pressure rise is predictive of vision improvement after intravitreal triamcinolone acetonide for diabetic macular oedema: a retrospective analysis of data from a randomised controlled trial
BMC Ophthalmology (2014)